Literature DB >> 28339911

A null variant in the apolipoprotein L3 gene is associated with non-diabetic nephropathy.

Karl L Skorecki1,2, Jessica H Lee3, Carl D Langefeld4,5, Saharon Rosset6, Shay Tzur1,2, Walter G Wasser2,7, Revital Shemer1, Gregory A Hawkins8, Jasmin Divers4,5, Rulan S Parekh9,10,11, Man Li12,13, Matthew G Sampson14, Matthias Kretzler15, Martin R Pollak3, Shrijal Shah3, Daniel Blackler3, Brendan Nichols3, Michael Wilmot3, Seth L Alper3, Barry I Freedman5,16, David J Friedman3.   

Abstract

Background: Inheritance of apolipoprotein L1 gene (APOL1) renal-risk variants in a recessive pattern strongly associates with non-diabetic end-stage kidney disease (ESKD). Further evidence supports risk modifiers in APOL1-associated nephropathy; some studies demonstrate that heterozygotes possess excess risk for ESKD or show earlier age at ESKD, relative to those with zero risk alleles. Nearby loci are also associated with ESKD in non-African Americans.
Methods: We assessed the role of the APOL3 null allele rs11089781 on risk of non-diabetic ESKD. Four cohorts containing 2781 ESKD cases and 2474 controls were analyzed.
Results: Stratifying by APOL1 risk genotype (recessive) and adjusting for African ancestry identified a significant additive association between rs11089781 and ESKD in each stratum and in a meta-analysis [meta-analysis P  =  0.0070; odds ratio (OR) = 1.29]; ORs were consistent across APOL1 risk strata. The biological significance of this association is supported by the finding that the APOL3 gene is co-regulated with APOL1, and that APOL3 protein was able to bind to APOL1 protein. Conclusions: Taken together, the genetic and biological data support the concept that other APOL proteins besides APOL1 may also influence the risk of non-diabetic ESKD.
© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  APOL1; APOL3; African American; FSGS; chronic kidney disease

Mesh:

Substances:

Year:  2018        PMID: 28339911      PMCID: PMC5837424          DOI: 10.1093/ndt/gfw451

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  26 in total

1.  APOL1 and progression of nondiabetic nephropathy.

Authors:  Nicholette D Palmer; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2013-06-27       Impact factor: 10.121

2.  End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.

Authors:  Barry I Freedman; Carl D Langefeld; Kelly K Andringa; Jennifer A Croker; Adrienne H Williams; Neva E Garner; Daniel J Birmingham; Lee A Hebert; Pamela J Hicks; Mark S Segal; Jeffrey C Edberg; Elizabeth E Brown; Graciela S Alarcón; Karen H Costenbader; Mary E Comeau; Lindsey A Criswell; John B Harley; Judith A James; Diane L Kamen; S Sam Lim; Joan T Merrill; Kathy L Sivils; Timothy B Niewold; Neha M Patel; Michelle Petri; Rosalind Ramsey-Goldman; John D Reveille; Jane E Salmon; Betty P Tsao; Keisha L Gibson; Joyce R Byers; Anna K Vinnikova; Janice P Lea; Bruce A Julian; Robert P Kimberly
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

3.  The MYH9/APOL1 region and chronic kidney disease in European-Americans.

Authors:  Conall M O'Seaghdha; Rulan S Parekh; Shih-Jen Hwang; Man Li; Anna Köttgen; Josef Coresh; Qiong Yang; Caroline S Fox; W H Linda Kao
Journal:  Hum Mol Genet       Date:  2011-03-23       Impact factor: 6.150

4.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

5.  APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease.

Authors:  Shay Tzur; Saharon Rosset; Karl Skorecki; Walter G Wasser
Journal:  Nephrol Dial Transplant       Date:  2012-02-22       Impact factor: 5.992

6.  Evolution of the primate trypanolytic factor APOL1.

Authors:  Russell Thomson; Giulio Genovese; Chelsea Canon; Daniella Kovacsics; Matthew K Higgins; Mark Carrington; Cheryl A Winkler; Jeffrey Kopp; Charles Rotimi; Adebowale Adeyemo; Ayo Doumatey; George Ayodo; Seth L Alper; Martin R Pollak; David J Friedman; Jayne Raper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-07       Impact factor: 11.205

7.  Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1.

Authors:  Alok K Sharma; David J Friedman; Martin R Pollak; Seth L Alper
Journal:  FEBS J       Date:  2016-04-01       Impact factor: 5.542

8.  Re-Sequencing of the APOL1-APOL4 and MYH9 Gene Regions in African Americans Does Not Identify Additional Risks for CKD Progression.

Authors:  Gregory A Hawkins; David J Friedman; Lingyi Lu; David R McWilliams; Jeff W Chou; Satria Sajuthi; Jasmin Divers; Rulan S Parekh; Man Li; Giulio Genovese; Martin R Pollack; Pamela J Hicks; Donald W Bowden; Lijun Ma; Barry I Freedman; Carl D Langefeld
Journal:  Am J Nephrol       Date:  2015-09-08       Impact factor: 3.754

9.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Authors:  Shay Tzur; Saharon Rosset; Revital Shemer; Guennady Yudkovsky; Sara Selig; Ayele Tarekegn; Endashaw Bekele; Neil Bradman; Walter G Wasser; Doron M Behar; Karl Skorecki
Journal:  Hum Genet       Date:  2010-07-16       Impact factor: 4.132

10.  Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1.

Authors:  Brendan Nichols; Prachi Jog; Jessica H Lee; Daniel Blackler; Michael Wilmot; Vivette D'Agati; Glen Markowitz; Jeffrey B Kopp; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  Kidney Int       Date:  2014-08-06       Impact factor: 10.612

View more
  14 in total

1.  Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions.

Authors:  Carl D Langefeld; Mary E Comeau; Maggie C Y Ng; Meijian Guan; Latchezar Dimitrov; Poorva Mudgal; Mitzie H Spainhour; Bruce A Julian; Jeffrey C Edberg; Jennifer A Croker; Jasmin Divers; Pamela J Hicks; Donald W Bowden; Gary C Chan; Lijun Ma; Nicholette D Palmer; Robert P Kimberly; Barry I Freedman
Journal:  Kidney Int       Date:  2018-06-07       Impact factor: 10.612

Review 2.  Mechanisms of Injury in APOL1-associated Kidney Disease.

Authors:  Lijun Ma; Jasmin Divers; Barry I Freedman
Journal:  Transplantation       Date:  2019-03       Impact factor: 4.939

3.  The Mechanism of Kidney Disease Due to APOL1 Risk Variants.

Authors:  Etienne Pays
Journal:  J Am Soc Nephrol       Date:  2020-09-17       Impact factor: 10.121

4.  APOL1 risk variants in kidney transplantation: a modulation of immune cell function.

Authors:  Andrew F Malone
Journal:  J Clin Invest       Date:  2021-11-15       Impact factor: 14.808

Review 5.  Apolipoprotein L1 nephropathies: 2017 in review.

Authors:  Jeffrey B Kopp; Hila Roshanravan; Koji Okamoto
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-05       Impact factor: 2.894

6.  Common homozygosity for predicted loss-of-function variants reveals both redundant and advantageous effects of dispensable human genes.

Authors:  Antonio Rausell; Yufei Luo; Marie Lopez; Yoann Seeleuthner; Franck Rapaport; Antoine Favier; Peter D Stenson; David N Cooper; Etienne Patin; Jean-Laurent Casanova; Lluis Quintana-Murci; Laurent Abel
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-02       Impact factor: 11.205

7.  Effect of a Single Apolipoprotein L1 Gene Nephropathy Variant on the Risk of Advanced Lupus Nephritis in Brazilians.

Authors:  Gisele Vajgel; Suelen Cristina Lima; Diego Jeronimo S Santana; Camila B L Oliveira; Denise Maria N Costa; Pamela J Hicks; Maria Alina G M Cavalcante; Carl D Langefeld; Lucila Maria Valente; Sergio Crovella; Gianna Mastroianni Kirsztajn; Barry I Freedman; Paula Sandrin-Garcia
Journal:  J Rheumatol       Date:  2019-11-15       Impact factor: 4.666

Review 8.  APOL1 Nephropathy: From Genetics to Clinical Applications.

Authors:  David J Friedman; Martin R Pollak
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-02       Impact factor: 8.237

Review 9.  Apolipoprotein L1 and mechanisms of kidney disease susceptibility.

Authors:  Leslie A Bruggeman; John R Sedor; John F O'Toole
Journal:  Curr Opin Nephrol Hypertens       Date:  2021-05-01       Impact factor: 2.894

10.  APOL1 at 10 years: progress and next steps.

Authors:  Barry I Freedman; Jeffrey B Kopp; Matthew G Sampson; Katalin Susztak
Journal:  Kidney Int       Date:  2021-03-29       Impact factor: 18.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.